MARKET

CELH

CELH

Celsius Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

64.68
+1.51
+2.38%
After Hours: 64.66 -0.02 -0.03% 17:03 01/22 EST
OPEN
62.71
PREV CLOSE
63.18
HIGH
66.38
LOW
61.75
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
70.66
52 WEEK LOW
3.220
MARKET CAP
4.63B
P/E (TTM)
849.93
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20)
Benzinga · 1d ago
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 2d ago
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 01/15 12:57
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)
Benzinga · 01/14 12:56
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12)
Benzinga · 01/13 12:25
The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11)
Benzinga · 01/12 13:15
Celsius Set to Join S&P SmallCap 600® Index
, /PRNewswire/ -- (Nasdaq: CELH) Celsius Holdings Inc., maker of the leading global fitness drink, CELSIUS®, today announced that the Company will be added to the S&P SmallCap 600 Index, effective , prior to the market open. The S&P SmallCap 600 measures ...
PR Newswire - PRF · 01/06 14:10
Celsius Set to Join S&P SmallCap 600® Index
PR Newswire · 01/06 14:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CELH. Analyze the recent business situations of Celsius Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CELH stock price target is 35.00 with a high estimate of 40.00 and a low estimate of 29.00.
EPS
Institutional Holdings
Institutions: 143
Institutional Holdings: 39.94M
% Owned: 55.74%
Shares Outstanding: 71.65M
TypeInstitutionsShares
Increased
26
6.00M
New
44
3.17M
Decreased
45
2.28M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Non-Alcoholic Beverages
-0.76%
Beverages
-1.10%
Key Executives
Co-Chairman/Independent Director
Tony Lau
Co-Chairman/Independent Director
William Milmoe
President/Chief Executive Officer/Director
John Fieldly
Chief Financial Officer
Edwin Negron-Carballo
Independent Director
Nicholas Castaldo
Independent Director
Kevin Harrington
Independent Director
Hal Kravitz
Independent Director
Caroline Levy
Independent Director
Thomas Lynch
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CELH
Celsius Holdings, Inc. is engaged in the development, marketing, sale and distribution of functional calorie-burning fitness beverages under the Celsius brand name. The Company's products are sweetened with sucralose, which is suitable for consumers whose sugar intake is restricted. The Company's Celsius brand uses ingredients and supplements, such as green tea (EGCG), ginger, calcium, chromium, B vitamins and vitamin C. The Company outsources the manufacturing process to third-party co-packers. It offers Celsius brand in various flavors, including carbonated flavors, such as orange, wild berry and cola, and non-carbonated green tea raspberry/acai, and green tea/peach mango. Its beverages are sold in 12-ounce cans. It also markets the ingredients in powdered form in individual On-The-Go packets, as well as multiple serving canisters. It sells Celsius brand across retail segments, which include supermarkets and convenience stores.
More

Webull offers kinds of Celsius Holdings, Inc. stock information, including NASDAQ:CELH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELH stock methods without spending real money on the virtual paper trading platform.